Incidence and significance of FLT3-ITD and NPM1 mutations in patients with normal karyotype acute myeloid leukaemia
- First Online:
- 132 Downloads
Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haematopoietic progenitor cells. Approximately half of all adult AML patients have a normal karyotype (NK-AML) and an intermediate risk prognosis.
To determine the incidence and prognostic significance of NPM1 and FLT3-ITD mutations in a population of patients with NK-AML.
FLT3-ITD and NPM1 mutation status was retrospectively sought in presentation samples from 44 NK-AML patients.
FLT3-ITD and NPM1 mutations were detected in 45.5 and 54.5% of patients, respectively, allowing stratification according to genotype.
FLT3-ITD and NPM1 mutation status can be defined in NK-AML. Prospective screening for these mutations is advocated in all NK-AML patients, as the genotype is of clinical importance when considering treatment options including stem cell transplantation.
KeywordsAML Nucleophosmin FLT3-ITD Normal karyotype Prognosis Genotype
- 1.Swerdlow SH, Campo E, Harris NL (eds) (2008) World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, LyonGoogle Scholar
- 4.Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK MRC trials. Blood 116:354–365Google Scholar
- 9.Kottaridis P, Gale RE, Frew ME et al (2001) The presence of a FLT-3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the UK MRC AML 10 and 12 trials. Blood 98:1752–1759CrossRefPubMedGoogle Scholar
- 10.Schnittger S, Schoch C, Dugas M et al (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detction of minimal residual disease. Blood 100:59–66CrossRefPubMedGoogle Scholar
- 21.Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:431–438CrossRefPubMedGoogle Scholar